PMID- 26322158
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150831
LR  - 20220408
IS  - 1948-9358 (Print)
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 6
IP  - 10
DP  - 2015 Aug 25
TI  - Effect of proton pump inhibitors on glycemic control in patients with diabetes.
PG  - 1122-31
LID - 10.4239/wjd.v6.i10.1122 [doi]
AB  - Gastrin is a linear peptide hormone which is secreted mostly in the stomach 
      pyloric antrum G cells. Although the main role of this hormone is the promotion 
      of the secretion of gastric acid from the stomach parietal cells, gastrin can 
      also behave as a growth factor and stimulate gastric cell proliferation. It is 
      also reported that gastrin promotes beta cell neogenesis in the pancreatic ductal 
      complex, modest pancreatic beta cell replication, and improvement of glucose 
      tolerance in animal models, in which the remodeling of pancreatic tissues is 
      promoted. These findings suggest the possibility that gastrin has the potential 
      to promote an increase of beta cell mass in pancreas, and therefore that gastrin may 
      improve glucose tolerance. Proton pump inhibitors (PPIs) are wildly used 
      clinically for the therapy of gastro-esophageal reflex disease, gastritis due to 
      excess stomach acid, and gastric ulcers. PPIs indirectly elevate serum gastrin 
      levels via a negative feedback effect. Recent evidence has revealed the 
      beneficial effect of PPIs on glycemic control especially in patients with type 2 
      diabetes mellitus (T2DM), probably via the elevation of the levels of serum 
      gastrin, although the detailed mechanism remains unclear. In addition, the 
      beneficial effects of a combination therapy of gastrin or a PPI with a 
      glucagon-like peptide-1 receptor agonist on glycemic control in animal models 
      have been demonstrated. Although PPIs may be possible candidates for a new 
      approach in the therapy of diabetes, a prospective, long-term, randomized, 
      double-blind, placebo-controlled study is needed to establish the effect of PPIs 
      on glycemic control in a large number of patients with T2DM.
FAU - Takebayashi, Kohzo
AU  - Takebayashi K
AD  - Kohzo Takebayashi, Toshihiko Inukai, Department of Internal Medicine, Dokkyo 
      Medical University Koshigaya Hospital, Koshigaya, Saitama 343-8555, Japan.
FAU - Inukai, Toshihiko
AU  - Inukai T
AD  - Kohzo Takebayashi, Toshihiko Inukai, Department of Internal Medicine, Dokkyo 
      Medical University Koshigaya Hospital, Koshigaya, Saitama 343-8555, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC4549663
OTO - NOTNLM
OT  - Gastrin
OT  - Glycemic control
OT  - Proton pump inhibitors
OT  - Type 2 diabetes
EDAT- 2015/09/01 06:00
MHDA- 2015/09/01 06:01
PMCR- 2015/08/25
CRDT- 2015/09/01 06:00
PHST- 2015/04/29 00:00 [received]
PHST- 2015/07/06 00:00 [revised]
PHST- 2015/07/24 00:00 [accepted]
PHST- 2015/09/01 06:00 [entrez]
PHST- 2015/09/01 06:00 [pubmed]
PHST- 2015/09/01 06:01 [medline]
PHST- 2015/08/25 00:00 [pmc-release]
AID - 10.4239/wjd.v6.i10.1122 [doi]
PST - ppublish
SO  - World J Diabetes. 2015 Aug 25;6(10):1122-31. doi: 10.4239/wjd.v6.i10.1122.